Efficacy and safety of ixekizumab in Chinese patients with plaque psoriasis

To the Editor:Psoriasis is a common,chronic papulosquamous skin disease occurring worldwide,presenting at any age,and leading to a substantial burden for individuals and society.Interleukin(IL)-17A is considered the key effector cytokine inducing psoriatic inflammation and tissue damage.[1]Ixekizumab is a humanized monoclonal immunoglobulin G specifically binding to and inhibiting IL-17A.The efficacy and safety of ixekizumab in patients with psoriasis have been clearly demonstrated in several randomized clinical trials,namely UNCOVER-1,UNCOVER-2,UNCOVER-3,and UNCOVER-J.[2,3]However,the clinical research data on ixekizumab in Chinese psoriasis patients remain limited.